The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Etranacogene Dezaparvovec for Hemophilia B: Single-Dose Gene Therapy

AAV5-vectored Padua factor IX gene therapy enabling sustained factor IX expression and freedom from prophylaxis

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Hematoloji department. Book Appointment →

What is Etranacogene Dezaparvovec for Hemophilia B: Single-Dose Gene Therapy?

Etranacogene dezaparvovec uses adeno-associated virus serotype 5 vector to deliver Padua variant F9 gene to hepatocytes for sustained factor IX expression.

Padua variant features arginine substitution at position 338 conferring 5-8 fold higher specific activity than wild-type factor IX.

Single intravenous infusion enables endogenous factor IX production with peak factor levels typically reaching 30-50% of normal.

Treatment indication includes adult patients with severe or moderately severe hemophilia B without inhibitors and adequate liver function.

Pre-existing neutralizing antibodies to AAV5 capsid preclude treatment necessitating screening before therapy planning.

Symptoms

Asymptomatic transaminase elevation occurs in majority of patients within first months requiring corticosteroid intervention to preserve transgene expression.
Infusion reactions including fever, chills and hypersensitivity may occur during or shortly after vector administration with premedication strategies.
Pre-existing factor IX inhibitor history precludes treatment given immune memory and risk of inhibitor recurrence.
Liver disease including viral hepatitis or significant fibrosis affects treatment safety requiring screening hepatology evaluation.
Loss of factor expression over years remains long-term concern with ongoing follow-up determining therapy durability.

Risk Factors

Pre-existing AAV5 neutralizing antibodies prevent treatment efficacy given vector neutralization before transduction.
Active or recent liver disease including viral hepatitis, NAFLD with significant fibrosis or alcohol use disorder requires evaluation.
History of factor IX inhibitor development precludes treatment given immune system primed to recognize factor IX.
Concurrent use of medications affecting hepatic function or metabolism requires careful coordination during treatment.
Limited long-term durability data and regulatory restrictions affect availability and informed consent discussions.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Established severe or moderately severe hemophilia B with inadequate response to standard prophylaxis warrants evaluation.
  • Recurrent breakthrough bleeding despite optimized factor prophylaxis suggests benefit from alternative approaches.
  • Joint disease progression on standard care indicates need for treatment intensification options.
  • Anti-AAV5 antibody screening as prerequisite before treatment planning during evaluation phase.
  • Comprehensive hematology evaluation at hemophilia treatment center coordinates multidisciplinary therapy considerations.

Treatment Methods

01
Pre-treatment screening including AAV5 antibody titer, liver function, hepatitis screening and inhibitor history confirms eligibility.
02
Single intravenous infusion of vector with appropriate venous access and monitoring during and after administration.
03
Corticosteroid management for transaminase elevations preserves transgene expression with prednisone tapers per established protocols.
04
Frequent factor IX level monitoring documents transgene activity with weekly assessments transitioning to less frequent intervals.
05
Long-term outcomes monitoring through patient registries documents durability of factor expression, breakthrough bleeding episodes and safety profile over years to decades supporting evidence-based care for this transformative therapy.

Which Department to Visit?

You can visit our Hematoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Hematoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.